BRISBANE, Calif.--(BUSINESS WIRE)--
Innoviva, Inc. (NASDAQ: INVA) announced today that it will report
financial results for the fourth quarter and year ended December 31,
2017 after market close on February 8, 2017. Following the earnings
release, Innoviva management will host a webcast and conference call at
5:00 p.m. EDT/2:00 p.m. PDT to discuss the financial results and provide
a corporate update.
To participate in the live call, dial (877) 837-3908 from the U.S., or
(973) 890-8166 for international callers, and enter Conference ID:
2397629. A live webcast of the call will be available by following this
Earnings Call Webcast or from the investor relations section of the
company website at www.inva.com
and will be archived for 30 days. A telephone replay of the call will be
available through February 15, by dialing (404) 537-3406.
Innoviva is focused on bringing compelling new medicines to patients in
areas of unmet need by leveraging its significant expertise in the
development, commercialization and financial management of
bio-pharmaceuticals. Innoviva's portfolio is anchored by the respiratory
assets partnered with Glaxo Group Limited (GSK), including RELVAR®/BREO®
ELLIPTA®, ANORO® ELLIPTA® and TRELEGY® ELLIPTA®, which were jointly
developed by Innoviva and GSK. Under the agreement with GSK, Innoviva is
eligible to receive associated royalty revenues from RELVAR®/BREO®
ELLIPTA® and ANORO® ELLIPTA®. In addition, Innoviva retains a 15 percent
economic interest in future payments made by GSK for TRELEGY® ELLIPTA®
and earlier-stage programs partnered with Theravance BioPharma, Inc. For
more information, please visit Innoviva's website at www.inva.com.
ANORO®, RELVAR®, BREO® and ELLIPTA® and TRELEGY® ELLIPTA®, are
trademarks of the GlaxoSmithKline group of companies.
View source version on businesswire.com: http://www.businesswire.com/news/home/20180202005556/en/
Senior Vice President and Chief
Source: Innoviva, Inc.
News Provided by Acquire Media